Author: Dr Artin Mahdanian

WHO Guidelines: the mhGAP community toolkit field test version

By Dr Artin Mahdanian

Overview The mhGAP community toolkit: field test version is an integral part of WHO’s Mental Health Gap Action Programme (mhGAP), and aims at scaling up services for people with mental health conditions to achieve universal health coverage.  The toolkit provides guidance for programme managers on how to identify local mental health needs and tailor community services to match…

WHO Guidelines: Risk reduction of cognitive decline and dementia

By Dr Artin Mahdanian

Overview The WHO Guidelines on risk reduction of cognitive decline and dementia provide evidence-based recommendations on lifestyle behaviours and interventions to delay or prevent cognitive decline and dementia. Worldwide, around 50 million people have dementia and, with one new case every three seconds, the number of people with dementia is set to triple by 2050. The increasing…

Religion and Depression: A Review of the Literature

By Dr Artin Mahdanian

Abstract Background: Depressive disorders are among the most important causes of disability and can be considered a major contributor to the global burden of mental illnesses. Religious beliefs and practices have roots in the history of mankind and are broadly prevalent around the world. People with chronic medical and psychiatric conditions employ religion as a…

Can Geriatric Psychiatry Patients Complete Symptoms Self-Reports Using Tablets? A Randomized Study

By Dr Artin Mahdanian

Abstract Background: With our aging population and limited number of geriatric psychiatrists, innovations must be made in order to meet the growing demands for geriatric psychiatry services. Emerging technologies could greatly improve access to care and systematic data collection. Methods: This randomized study compared completion rates and time to completion (primary outcomes) when using iPad technology vs.…

Citalopram and escitalopram: adverse cardiac outcomes in medically ill inpatients

By Dr Artin Mahdanian

Serotonin selective reuptake inhibitors (SSRIs) have widely replaced older tricyclic antidepressants (TCAs) in the treatment of depression and anxiety over the years, given their safer cardiac profile [Glassman, 1998]. Even at therapeutic doses, TCAs commonly cause a slowing of intraventricular conduction through their sodium-channel blocking properties, leading to prolonged PR, QRS and QT intervals [Pacher…

Selective Serotonin Re-Uptake Inhibitors and Hyponatremia in Acutely Medically-Ill Inpatients

By Dr Artin Mahdanian

Abstract Background: Selective Serotonin Reuptake Inhibitors (SSRIs) have become the mainstay of treatment for depression, anxiety, and many other conditions. However, they have been associated with an increased risk of hyponatremia. Little is known about the risk of SSRI-associated hyponatremia in certain potentially at-risk populations, such as patients with acute medical illnesses. Objective: The main objective of…